Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemoradiation schedules--what radiotherapy?

R Glynne-Jones1, D Sebag-Montefiore

  • 1Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK. rgjones@mtvern.co.uk

European Journal of Cancer (Oxford, England : 1990)
|January 23, 2002
PubMed
Summary

Optimal synchronous chemoradiation (SCRT) schedules remain elusive. Future research must prioritize less toxic, more effective SCRT strategies, rigorously documenting outcomes in randomized trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic complement protein levels as biomarkers of chemoradiotherapy response in anal squamous cell carcinoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Radiating Excellence: A Decade of Pioneering Radiotherapy Trials and Collaborative Leadership at Leeds Cancer Research UK Clinical Trials Unit.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

The Impact of National Radiotherapy Guidelines: The UK Anal Cancer Story.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.

British journal of cancer·2022

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Synchronous chemoradiation (SCRT) is increasingly used for cancer management.
  • Current SCRT schedules are often empirically derived, potentially compromising radiotherapy parameters.
  • Limited high-quality randomized trials exist, with poor documentation of toxicity and long-term outcomes.

Purpose of the Study:

  • To review evidence from randomized trials on SCRT in various cancers.
  • To explore the impact of dose, fractionation, treatment gaps, and scheduling on SCRT outcomes.
  • To assess the real benefit of SCRT by examining local control and overall survival.

Main Methods:

  • Systematic review of randomized trials in lung, head and neck, esophageal, rectal, and anal cancers.
  • Analysis of endpoints including local control and overall survival.
  • Exploration of radiotherapy variables: total dose, fractionation, fraction size, treatment gaps, and scheduling.

Main Results:

  • Optimal SCRT schedules have not been established.
  • Current SCRT regimens are associated with significant acute toxicity and a high risk of local failure.
  • Long-term survival and functional outcomes are often poorly documented.

Conclusions:

  • There is a critical need for novel, more effective, and less toxic SCRT strategies.
  • Future randomized trials must meticulously report acute toxicity and radiotherapy details (field size, organ-at-risk dose).
  • This will enable the derivation of optimal therapeutic ratios for SCRT.

Related Experiment Videos